Folgen
Pie Huda
Pie Huda
Postdoctoral Research Fellow, The University of Queensland
Bestätigte E-Mail-Adresse bei uq.edu.au
Titel
Zitiert von
Zitiert von
Jahr
Investigating the function of Fc‐specific binding of IgM to Plasmodium falciparum erythrocyte membrane protein 1 mediating erythrocyte rosetting
L Stevenson, P Huda, A Jeppesen, E Laursen, JA Rowe, A Craig, ...
Cellular microbiology 17 (6), 819-831, 2015
692015
Invisible detergents for structure determination of membrane proteins by small‐angle neutron scattering
SR Midtgaard, TA Darwish, MC Pedersen, P Huda, AH Larsen, ...
The FEBS journal 285 (2), 357-371, 2018
572018
Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin
T Tieu, M Wojnilowicz, P Huda, KJ Thurecht, H Thissen, NH Voelcker, ...
Biomaterials Science 9 (1), 133-147, 2021
282021
Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets
S Niamsuphap, C Fercher, S Kumble, P Huda, SM Mahler, CB Howard
Expert Opinion on Drug Delivery 17 (9), 1189-1211, 2020
282020
PET/CT Based In Vivo Evaluation of 64Cu Labelled Nanodiscs in Tumor Bearing Mice
P Huda, T Binderup, MC Pedersen, SR Midtgaard, DR Elema, A Kjær, ...
PLoS One 10 (7), e0129310, 2015
262015
Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption
PW Janowicz, ZH Houston, J Bunt, NL Fletcher, CA Bell, G Cowin, ...
Biomaterials 283, 121416, 2022
172022
Mg2+-dependent conformational equilibria in CorA and an integrated view on transport regulation
NT Johansen, M Bonaccorsi, T Bengtsen, AH Larsen, FG Tidemand, ...
Elife 11, e71887, 2022
132022
Pre-targeting of polymeric nanomaterials to balance tumour accumulation and clearance
NL Fletcher, A Prior, O Choy, J Humphries, P Huda, S Ghosh, ZH Houston, ...
Chemical Communications 58 (57), 7912-7915, 2022
102022
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia
E Moles, CB Howard, P Huda, M Karsa, H McCalmont, K Kimpton, A Duly, ...
Science Translational Medicine 15 (696), eabm1262, 2023
82023
Confined microemulsion sono-polymerization of poly (ethylene glycol) nanoparticles for targeted delivery
Z Gao, X Li, K Zhao, H Geng, P Zhang, Y Ju, P Huda, CB Howard, ...
Chemical Communications 58 (56), 7777-7780, 2022
72022
Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma
S Ghosh, NL Fletcher, P Huda, ZH Houston, CB Howard, ME Lund, Y Lu, ...
Molecular pharmaceutics 20 (3), 1549-1563, 2023
42023
Clinical development of an anti-GPC-1 antibody for the treatment of cancer
S Ghosh, P Huda, N Fletcher, D Campbell, KJ Thurecht, B Walsh
Expert Opinion on Biological Therapy 22 (5), 603-613, 2022
42022
Development of targeted micelles and polymersomes prepared from degradable RAFT-based diblock copolymers and their potential role as nanocarriers for chemotherapeutics
SE Ahmed, NL Fletcher, AR Prior, P Huda, CA Bell, KJ Thurecht
Polymer Chemistry 13 (27), 4004-4017, 2022
32022
Development and validation of a targeted treatment for brain tumors using a multi-drug loaded, relapse-resistant polymeric theranostic
W Chu, ZH Houston, NL Fletcher, P Huda, M Ahamed, TX Lim, BW Day, ...
Biomacromolecules 24 (6), 2674-2690, 2023
22023
Antibody-based formats to target glioblastoma: overcoming barriers to protein drug delivery
S Ghosh, P Huda, NL Fletcher, CB Howard, B Walsh, D Campbell, ...
Molecular Pharmaceutics 19 (5), 1233-1247, 2022
22022
Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
A Logan, CB Howard, P Huda, K Kimpton, Z Ma, KJ Thurecht, ...
Journal of Controlled Release 367, 806-820, 2024
12024
RAFT Polymer–Antibody Conjugation: Squaramide Ester Chemistry Leads to Conjugates with a Therapeutic Anti-EGFR Antibody with Full Retention of Activity and Increased Tumor …
A Ardana, S Ghosh, P Huda, NL Fletcher, KJ Thurecht, CC Williams
Molecular Pharmaceutics 20 (6), 3073-3087, 2023
12023
Combined SAXS and Microfludics for time-resolved structural studies of bimolecules
L Arleth, GV Jensen, P Huda, S Skou, W Shang, S Chakravarthy
Acta Cryst 70, C609, 2017
12017
Click‐on Antibody Fragments for Customisable Targeted Nanomedicines–Site‐specific Tetrazine and Azide Functionalisation through Non‐canonical Amino Acid incorporation
P Huda, J Humphries, NL Fletcher, CB Howard, KJ Thurecht, CA Bell
Chemistry‐Methods 4 (2), e202300036, 2024
2024
Immuno-PET agents for targeting glioblastoma
S Ghosh, P Huda, N Fletcher, C Howard, Y Lu, D Campbell, B Walsh, ...
Internal Medicine Journal 52 (Supplement 2), 24-24, 2022
2022
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20